Two separate studies demonstrated that truncating mutations in HDAC2 in human cancers with microsatellite instability led to a loss of HDAC2 protein expression and enzymatic activity and resulted in resistance to HDACi, highlighting the importance or determing HDAC2 mutational status prior to treatment [83, 84]. This evidence concerns the gene HDAC2 and cancer.